Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index
12 September 2022 - 9:00PM
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage
pharmaceutical company with a Research & Development
(“R&D”) innovation engine that aims to discover, develop, and
ultimately deliver impactful medicines to patients, today announced
non-clinical pharmacokinetic (PK) and safety data in non-human
primates (NHPs) for LB101 (PD-L1xCD47), its first LockBody®
candidate for solid tumors. Findings from these data reinforce the
potential of its LockBody platform to minimize the systemic effects
of potent immune effectors and significantly improve the
therapeutic index. Centessa management will discuss the data during
the Morgan Stanley 20th Annual Global Healthcare Conference taking
place today at 8:45 am ET.
“These data, together with the
non-clinical data presented at ASCO earlier this year, continue to
validate our novel LockBody pharmacology, which leverages the
natural cleaving of the human IgG-derived hinge to deliver powerful
effectors like anti-CD47 into the tumor environment,” said Saurabh
Saha, MD, PhD, Chief Executive Officer of Centessa. “Whereas
current therapies targeting CD47 are encumbered with severe
toxicities due to peripheral activity on circulating red blood
cells, LB101 has the potential to optimally deliver anti-PD-L1
activity plus targeted anti-CD47 activity to the tumor
micro-environment. These new non-clinical data demonstrate systemic
delivery of high doses of LB101 without hematological toxicity in
non-human primates, resulting in the potential to achieve an
enhanced therapeutic index, increased anti-tumor activity, and
enable meaningful treatment for patients with solid tumors. We look
forward to advancing LB101 into the clinic and plan to submit an
IND late this year.”
In the study, male and female
cynomolgus monkeys were administered LB101 intravenously, every 7
days over 28 days (q7 days x 4) at doses of 5mg/kg, 20mg/kg, and
50mg/kg. The pharmacokinetics of LB101 were assessed and exhibited
a typical IgG1-like PK profile. There were no adverse changes in
hematologic parameters (including no anemia and no
thrombocytopenia), no changes in body weights and no adverse
toxicology findings.
Event: Morgan Stanley 20th Annual Global
Healthcare ConferenceDate: Monday, September 12,
2022Location: New York City, NYFireside
Chat Time: 8:45 AM ET
Access to the live and archived recording of the webcast of the
fireside chat, as well as a copy of the Company’s slides that will
be used at the conference, will be available under the “Events and
Publications” tab on the investor relations section of the Centessa
Pharmaceuticals website at
https://investors.centessa.com/events-presentations.
About Centessa PharmaceuticalsCentessa
Pharmaceuticals plc is a clinical-stage pharmaceutical company with
an R&D innovation engine that aims to discover, develop, and
ultimately deliver impactful medicines to patients. Our programs
span discovery-stage to late-stage development and cover a range of
high-value indications in rare diseases and immuno-oncology. We are
led by a management team with extensive R&D experience,
providing direct guidance to our program teams to rapidly advance
our candidates from research through all stages of development. For
more information, visit www.centessa.com, which does not form part
of this release.
Forward Looking StatementsThis press release
contains forward-looking statements. These statements may be
identified by words such as “may,” “might,” “will,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “objective,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“continue,” “ongoing,” “aim,” “seek,” and variations of these words
or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including statements related to the
Company’s ability to deliver impactful medicines to patients; the
ability of our management team and board to drive execution of the
Company’s portfolio of programs; our asset-centric business model
and the intended advantages and benefits thereof; research and
clinical development plans and the timing thereof; the scope,
progress, results and costs of developing our product candidates or
any other future product candidates; the development and
therapeutic potential of our product candidates, including LB101,
and our LockBody platform; strategy; regulatory matters, including
the timing and likelihood of submitting an IND and the success of
obtaining authorizations to initiate or continue clinical trials or
market any products; and the market size and opportunity for our
product candidates. Any forward-looking statements in this press
release are based on our current expectations, estimates and
projections only as of the date of this release and are subject to
a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks related to the
safety and tolerability profile of our product candidates; our
ability to protect and maintain our intellectual property position;
business (including commercial viability), regulatory, economic and
competitive risks, uncertainties, contingencies and assumptions
about the Company; risks inherent in developing product candidates
and technologies; future results from our ongoing and planned
clinical trials; our ability to obtain adequate financing,
including through our financing facility with Oberland, to fund our
planned clinical trials and other expenses; trends in the industry;
the legal and regulatory framework for the industry, including the
receipt and maintenance of clearances to conduct or continue
clinical testing; future expenditures risks related to our
asset-centric corporate model; the risk that any one or more of our
product candidates will not be successfully developed and/or
commercialized; the risk that the results of non-clinical studies
or clinical studies will not be predictive of future results in
connection with future studies; geo-political risks such as the
Russia-Ukraine war and risks related to the ongoing COVID-19
pandemic including the effects of the Delta, Omicron and any other
variants. These and other risks concerning our programs and
operations are described in additional detail in our Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q, and our other
reports, which are on file with the U.S. Securities and Exchange
Commission (SEC). We explicitly disclaim any obligation to update
any forward-looking statements except to the extent required by
law.
Contact:
Kristen K. Sheppard, Esq.SVP of Investor Relations
investors@centessa.com
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Aug 2023 to Aug 2024